Sciwind Biosciences GLP-1 drug ecnoglutide helped patients lose over 15% body weight in trials, rivaling Eli Lilly Zepbound and Novo Nordisk Wegovy. With approval expected in 2026, Sciwind aims for 10% of China obesity drug market and is expanding overseas via licensing deals and collaborations.